Aimco Pesticides reported a consolidated net loss of Rs 12.20 crore for FY26, a 68% increase from the previous year, as revenue fell 22% to Rs 153.88 crore. Management blamed global inventory destocking and pricing pressure for the performance dip. Despite the financial headwinds, the company is pushing ahead with new product commercialization and market expansion into Brazil and new Indian states to stabilize future earnings.
Aimco Pesticides FY26 Loss Widens to Rs 12.20 Crore
Consolidated Net Loss: Rs 12.20 Crore | Revenue from Operations: Rs 153.88 Crore
Reader Takeaway: New product pipelines and Brazilian expansion offer growth potential, but high-cost inventories and industry-wide pricing pressure persist.
What just happened
Aimco Pesticides has reported its consolidated financial results for the fiscal year ending 2026, revealing a widening net loss of Rs 12.20 crore, compared to Rs 7.24 crore in FY25. Revenue from operations dropped 22.15% year-on-year to Rs 153.88 crore. EBITDA losses also deepened, moving to Rs 10.55 crore from Rs 2.40 crore in the previous year, reflecting compressed margins amid a challenging global agrochemical environment.
Why this matters
The results highlight the ongoing struggle for mid-cap agrochemical firms navigating a period of global supply chain destocking and intense price competition from Chinese manufacturers. For shareholders, the widening loss is a material concern, though management remains focused on operational pivot points, including the commercialization of new molecules and geographic diversification into the Brazilian market via new product registrations.
Strategic Developments
To mitigate export reliance, Aimco is expanding its branded formulations footprint into Madhya Pradesh, Rajasthan, Chhattisgarh, and Kerala. On the technical side, two new molecules are currently in small-scale production, with a third in the pilot phase. Additionally, the Board has approved the sale of a Mumbai-based property for Rs 4.77 crore to optimize resources.
Risks to watch
Investors should monitor the company's ability to clear high-cost inventories and manage margin pressure. Operational risks remain elevated due to monsoon dependency, raw material price volatility, and the prevalence of counterfeit products in the domestic market. The company did not recommend a dividend for the fiscal year.
What to track next
The 39th Annual General Meeting is scheduled for September 25, 2026, where the re-appointment of Dr. Samir Pradip Dave as Managing Director will be addressed. Future updates on the commercialization timeline for new molecules and signs of margin recovery will be the primary indicators of a potential turnaround.